ReviewArticle Chondrosarcoma and Peroxisome Proliferator-Activated Receptor

ligands could be a novel strategy against chondrosarcoma.Copyright © 2008 K. Nishida et al. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

[1]  S. Hukuda,et al.  Characterization of a newly established human chondrosarcoma cell line, CS-OKB , 1998, Virchows Archiv.

[2]  M. Hentz,et al.  PTHrP and Bcl-2: essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors. , 1998, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[3]  M. Romsdahl,et al.  Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading , 1977, Cancer.

[4]  J. Puzas,et al.  P‐glycoprotein expression in cartilaginous tumors , 1997, Journal of surgical oncology.

[5]  H. Yoshikawa,et al.  New cell lines with chondrocytic phenotypes from human chondrosarcoma , 2004, Virchows Archiv.

[6]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[7]  A. Huvos,et al.  p53 Mutations in Chondrosarcoma , 1998, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[8]  G. Atsumi,et al.  Early de Novo Gene Expression Is Required for 15-Deoxy-Δ12,14-prostaglandin J2-induced Apoptosis in Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[9]  B. Staels,et al.  Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation , 2000, Inflammation Research.

[10]  Chen,et al.  Is a Ligand for the Adipocyte Determination Factor PPARy , 2004 .

[11]  Y. Yano,et al.  Peroxisome Proliferator‐activated Receptor Gamma Activation Induces Cell Cycle Arrest via the p53‐independent Pathway in Human Anaplastic Thyroid Cancer Cells , 2002, Japanese journal of cancer research : Gann.

[12]  S. Ishihara,et al.  Peroxisome proliferator-activated receptor γ ligand-induced growth inhibition of human hepatocellular carcinoma , 2001, British Journal of Cancer.

[13]  G. Ailhaud,et al.  Cloning of a Protein That Mediates Transcriptional Effects of Fatty Acids in Preadipocytes , 1995, The Journal of Biological Chemistry.

[14]  B. Park,et al.  Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer , 2001, Current opinion in oncology.

[15]  K. Nishida,et al.  ADAMTS-9 is synergistically induced by interleukin-1β and tumor necrosis factor α in OUMS-27 chondrosarcoma cells and in human chondrocytes , 2005 .

[16]  B. Spiegelman,et al.  A Phase II Study of Troglitazone, an Activator of the PPARγ Receptor, in Patients with Chemotherapy‐Resistant Metastatic Colorectal Cancer , 2002 .

[17]  V. Lewis,et al.  What's new in musculoskeletal oncology. , 2007, The Journal of bone and joint surgery. American volume.

[18]  H. Inoue,et al.  Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth , 2002, International journal of cancer.

[19]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[20]  R. Sciot,et al.  Molecular analysis of the INK4A/INK4A‐ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression , 2004, The Journal of pathology.

[21]  T. Okumura,et al.  Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. , 2000, Cancer research.

[22]  R. Schneider-Stock,et al.  Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. , 2003, Pathology, research and practice.

[23]  R. Schneider-Stock,et al.  Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma , 2000, Virchows Archiv.

[24]  E. Conrad,et al.  Expression of cartilage extracellular matrix and potential regulatory genes in a new human chondrosarcoma cell line , 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[25]  P. Choong,et al.  CO‐EXPRESSION OF PARATHYROID HORMONE‐RELATED PROTEIN (PTHRP) AND PTH/PTHRP RECEPTOR IN CARTILAGINOUS TUMOURS: A MARKER FOR MALIGNANCY? , 2002, Pathology.

[26]  H. Inoue,et al.  Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-γ , 2002, British Journal of Cancer.

[27]  G. Schwartz,et al.  Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Esteller.  Aberrant DNA methylation as a cancer-inducing mechanism. , 2005, Annual review of pharmacology and toxicology.

[29]  B. Coughlan,et al.  p53 expression and DNA ploidy of cartilage lesions. , 1995, Human pathology.

[30]  M. Esteller.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future , 2002, Oncogene.

[31]  H. Inoue,et al.  Endostatin Inhibits Adhesion of Endothelial Cells to Collagen I via α2β1 Integrin, a Possible Cause of Prevention of Chondrosarcoma Growth , 2002 .

[32]  A. Cleton-Jansen,et al.  Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. , 2005, The Lancet. Oncology.

[33]  H. Inoue,et al.  Expression of connective tissue growth factor in cartilaginous tumors , 2000, Cancer.

[34]  R. Morrison,et al.  Role of PPARγ in Regulating a Cascade Expression of Cyclin-dependent Kinase Inhibitors, p18(INK4c) and p21(Waf1/Cip1), during Adipogenesis* , 1999, The Journal of Biological Chemistry.

[35]  R. Sciot,et al.  A phase II trial with rosiglitazone in liposarcoma patients , 2003, British Journal of Cancer.

[36]  B. Evers,et al.  Peroxisome proliferator-activated receptor γ ligand inhibits cell growth and invasion of human pancreatic cancer cells , 2002 .

[37]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 , 2000 .

[38]  J. Herman,et al.  DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. , 2001, Human molecular genetics.

[39]  H. Takahashi,et al.  Specific loss of chondromodulin‐I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo , 1999, FEBS letters.

[40]  A. Lindahl,et al.  Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues , 2000, International journal of cancer.

[41]  A. Llombart‐Bosch,et al.  Establishment and Characterization of a Continuous Human Chondrosarcoma Cell Line, ch-2879: Comparative Histologic and Genetic Studies with Its Tumor of Origin , 2003, Laboratory Investigation.

[42]  B. Spiegelman,et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Copland,et al.  Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1 , 2006, Oncogene.

[44]  Robert J. Marinelli,et al.  The gene expression profile of extraskeletal myxoid chondrosarcoma , 2005, The Journal of pathology.

[45]  T. Okumura,et al.  Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells , 2004, International journal of cancer.

[46]  Federica Briatore,et al.  Peroxisome Proliferator-Activated Receptor Ligands Affect Growth-Related Gene Expression in Human Leukemic Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[47]  S. Suster,et al.  Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers , 2007, Clinical Cancer Research.

[48]  H. Inoue,et al.  A new human chondrosarcoma cell line (OUMS‐27) that maintains chondrocytic differentiation , 1998, International journal of cancer.

[49]  Michael Brownlee,et al.  Inhibition of Cellular Proliferation through IκB Kinase-Independent and Peroxisome Proliferator-Activated Receptor γ-Dependent Repression of Cyclin D1 , 2001, Molecular and Cellular Biology.

[50]  C. Haslett,et al.  Prostaglandin D2 and Its Metabolites Induce Caspase-Dependent Granulocyte Apoptosis That Is Mediated Via Inhibition of IκBα Degradation Using a Peroxisome Proliferator-Activated Receptor-γ-Independent Mechanism1 , 2002, The Journal of Immunology.

[51]  R. Terek.  Recent advances in the basic science of chondrosarcoma. , 2006, The Orthopedic clinics of North America.

[52]  P. Fisher,et al.  Up-regulation of p21 Gene Expression by Peroxisome Proliferator-Activated Receptor γ in Human Lung Carcinoma Cells , 2004, Clinical Cancer Research.

[53]  A. Hamburger,et al.  15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells , 2002, British Journal of Cancer.

[54]  M. Takigawa,et al.  A clonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor. , 1990, Anticancer research.

[55]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.

[56]  B. Spiegelman,et al.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  H. Inoue,et al.  Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21. , 2005, Biochemical and biophysical research communications.